Intravitreal drug delivery in retinal disease: Are we out of our depth?

Expert Opinion on Drug Delivery

Volumn 11, Issue 10, 2014, Pages 1575-1590

  Thakur, Sachin S ^a   Barnett, Nigel L ^b,c,d   Donaldson, Mark J ^a   Parekh, Harendra S ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d QUEENSLAND EYE INSTITUTE   (Australia)

Author keywords

Drug delivery; Intravitreal delivery; Nanoparticles; Retina; Retinal barriers; Retinal models

Indexed keywords

NANOCARRIER; NANOPARTICLE; VIRUS VECTOR; DRUG; EYE DROPS;

ANTERIOR EYE CHAMBER; BLOOD RETINA BARRIER; DISEASE MODEL; DRUG ADMINISTRATION ROUTE; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; EPIRETINAL MEMBRANE; EX VIVO STUDY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTRAVITREAL DRUG ADMINISTRATION; INTRAVITREAL IMPLANT; NONHUMAN; RETINA DISEASE; REVIEW; ULTRASOUND; VITREOUS BODY; ANIMAL; RETINAL DISEASES;

ANIMALS; BLOOD-RETINAL BARRIER; DRUG DELIVERY SYSTEMS; HUMANS; INTRAVITREAL INJECTIONS; OPHTHALMIC SOLUTIONS; PHARMACEUTICAL PREPARATIONS; RETINAL DISEASES;

EID: 84907201808     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2014.927864     Document Type: Review

References (103)

1. Mariotti SP. Global data on visual impairments 2010. World Health Organization, Geneva, Switzerland; 2012
2. Thrimawithana TR, Young S, Bunt CR, et al. Drug delivery to the posterior segment of the eye. Drug Discov Today 2011;16(5):270-7
3. Peyman GA, Lad EM, Moshfeghi DM. Intravitreal injection of therapeutic agents. Retina 2009;29(7):875-912
4. Garhart C, Lakshminarayan V. Anatomy of the eye. In: Chen J, Cranton W, Fihn M, editors. Handbook of visual display technology. Canopus Publishing Ltd; Bristol, UK: 2012. p. 73-83
5. Kolb H, Fernandez E, Nelson R, Webvision The Organization of the Retina and Visual System [Internet]. University of Utah Health Sciences Center, Salt Lake City, UT; 1995. Available from: Http://www.ncbi. nlm.nih.gov/pubmed/21413389
6. Kevany BM, Palczewski K. Phagocytosis of retinal rod and cone photoreceptors. Physiology 2010;25(1):8-15
7. Hughes BA, Gallemore RP, Miller SS. Transport mechanisms in the retinal pigment epithelium. In: Marmor MW, editor. The retinal pigment epithelium. Oxford University Press; Oxford: 1998. p. 103-34
8. Liversidge J, McKay D, Mullen G, Forrester J. Retinal pigment epithelial cells modulate lymphocyte function at the blood-retina barrier by autocrine PGE2 and membrane-bound mechanisms. Cell Immunol 1993;149(2):315-30
9. Strauss O. The retinal pigment epithelium in visual function. Physiol Rev 2005;85(3):845-81
10. Newman E, Reichenbach A. The Müller cell: A functional element of the retina. Trends Neurosci 1996;19(8):307-12
11. Barnett NL, Pow DV, Robinson SR. Inhibition of Müller cell glutamine synthetase rapidly impairs the retinal response to light. Glia 2000;30(1):64-73
12. Remington LA. Retina. In: Remington LA, editor. Clinical anatomy and physiology of the visual system. 3 edition. Elsevier; St Louis, MO: 2012. p. 61-92
13. Bishop PN. Structural macromolecules and supramolecular organisation of the vitreous gel. Prog Retin Eye Res 2000;19(3):323-44
14. Holekamp NM. The vitreous gel: More than meets the eye. Am J Ophthalmol 2010;149(1):32-6; e1
15. Janoria KG, Gunda S, Boddu SHS, Mitra AK. Novel approaches to retinal drug delivery. Expert Opin Drug Deliv 2007;4(4):371-88
16. World Health Organization. Priority Eye Diseases 2014. 2014. Available from: Http://www.who.int/blindness/causes/priority/en/index.html
17. Tarr JM, Kaul K, Chopra M, et al. Pathophysiology of diabetic retinopathy. ISRN Ophthalmol 2013;2013:1-13
18. Medeiros FA, Lisboa R, Weinreb RN, et al. Retinal ganglion cell count estimates associated with early development of visual field defects in glaucoma. Ophthalmology 2013;120(4):736-44
19. Ding X, Patel M, Chan CC. Molecular pathology of age-related macular degeneration. Prog Retin Eye Res 2009;28(1):1-18
20. Caprioli J, Varma R. Intraocular pressure: Modulation as treatment for glaucoma. Am J Ophthalmol 2011;152(3):340-4; e2
21. Royal College of Ophthalmologists. Age-related macular degeneration: Guidelines for management. The Royal College of Ophthalmologists Scientific Department; London: 2009
22. Royal College of Ophthalmologists. Diabetic retinopathy guidelines. The Royal College of Ophthalmologists Scientific Department; London: 2012
23. Pescina S, Ferrari G, Govoni P, et al. In vitro permeation of bevacizumab through human sclera: Effect of iontophoresis application. J Pharm Pharmacol 2010;62(9):1189-94
24. Kim SH, Lutz RJ, Wang NS, Robinson MR. Transport barriers in transscleral drug delivery for retinal diseases. Ophthalmic Res 2007;39(5):244-54
25. Gilger BC, Abarca EM, Salmon JH, Patel S. Treatment of acute posterior uveitis in a porcine model by injection of triamcinolone acetonide into the suprachoroidal space using microneedles. Invest Ophthalmol Vis Sci 2013;54(4):2483-92
26. Patel SR, Lin AS, Edelhauser HF, Prausnitz MR. Suprachoroidal drug delivery to the back of the eye using hollow microneedles. Pharm Res 2011;28(1):166-76
27. Kadam RS, Williams J, Tyagi P, et al. Suprachoroidal delivery in a rabbit ex vivo eye model: Influence of drug properties, regional differences in delivery, and comparison with intravitreal and intracameral routes. Mol Vis 2013;19:1198-210
28. Wilson CG, Tan LE, Mains J. Principles of retinal drug delivery from within the vitreous. In: Kompella UB, Edelhauser HF, editors. Drug product development for the back of the eye. 2. Springer; New York: 2011. p. 125-58
29. Bettelheim FA, Zigler Jr. J.S. Regional mapping of molecular components of human liquid vitreous by dynamic light scattering. Exp Eye Res 2004;79(5):713-18
30. Sebag J. Ageing of the vitreous. Eye 1987;1(2):254-62
31. Tan LE, Orilla W, Hughes PM, et al. Effects of vitreous liquefaction on the intravitreal distribution of sodium fluorescein, fluorescein dextran, and fluorescent microparticles. Invest Ophthalmol Vis Sci 2011;52(2):1111-18
32. Laude A, Tan LE, Wilson CG, et al. Intravitreal therapy for neovascular agerelated macular degeneration and interindividual variations in vitreous pharmacokinetics. Prog Retin Eye Res 2010;29(6):466-75
33. Missel PJ. Hydraulic flow and vascular clearance influences on intravitreal drug delivery. Pharm Res 2002;19(11):1636-47
34. Xu Q, Boylan N, Suk J, et al. Nanoparticle diffusion in, and microrheology of, the bovine vitreous ex vivo. J Control Release 2013;167(1):76-84
35. Martens TF, Vercauteren D, Forier K, et al. Measuring the intravitreal mobility of nanomedicines with single-particle tracking microscopy. Nanomedicine 2013;8(12):1955-68
36. Candiello J, Cole GJ, Halfter W. Age-dependent changes in the structure, composition and biophysical properties of a human basement membrane. Matrix Biol 2010;29(5):402-10
37. Henrich P, Monnier C, Halfter W, et al. Nanoscale topographic and biomechanical studies of the human internal limiting membrane. Invest Ophthalmol Vis Sci 2012;53(6):2561-70
38. Goldenberg DT, Giblin FJ, Cheng M, et al. Posterior vitreous detachment with microplasmin alters the retinal penetration of intravitreal bevacizumab (Avastin) in rabbit eyes. Retina 2011;31(2):393-400
39. Meyer C, Krohne T, Holz F. Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans. Retina 2011;31(9):1877-84
40. Dalkara D, Kolstad KD, Caporale N, et al. Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous. Mol Ther 2009;17(12):2096-102
41. Li SK, Hao J, Liu H, Lee JH. MRI study of subconjunctival and intravitreal injections. J Pharm Sci 2012;101(7):2353-63
42. Nieto A, Hou H, Sailor MJ, et al. Ocular silicon distribution and clearance following intravitreal injection of porous silicon microparticles. Exp Eye Res 2013;116:161-8
43. Mains J, Tan LE, Wilson C, Urquhart A. A pharmacokinetic study of a combination of beta adrenoreceptor antagonists-In the isolated perfused ovine eye. Eur J Pharm Biopharm 2012;80(2):393-401
44. Cunha-Vaz J, Bernardes R, Lobo C. Blood-retinal barrier. Eur J Ophthalmol 2010;21(Suppl 6):S3-9
45. Pitkänen L, Ranta V-P, Moilanen H, Urtti A. Permeability of retinal pigment epithelium: Effects of permeant molecular weight and lipophilicity. Invest Ophthalmol Vis Sci 2005;46(2):641-6
46. Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 2012;119(10):2125-32
47. Haller JA, Bandello F, Belfort R Jr, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117(6):1134-46; e3
48. Jaffe GJ, Martin D, Callanan D, et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: Thirtyfour-week results of a multicenter randomized clinical study. Ophthalmology 2006;113(6):1020-7
49. Choonara YE, Pillay V, Danckwerts MP, et al. A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases. J Pharm Sci 2010;99(5):2219-39
50. Jain N, Stinnett SS, Jaffe GJ. Prospective study of a fluocinolone acetonide implant for chronic macular edema from central retinal vein occlusion: Thirty-six-month results. Ophthalmology 2012;119(1):132-7
51. ClinicalTrials.gov. A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis 2011. 2014. Available from: Http://www. clinicaltrials.gov/ct2/show/NCT00333814
52. Bansal R, Bansal P, Kulkarni P, et al. Wandering Ozurdex-implant. J Ophthalmic Inflamm Infect 2012;2(1):1-5
53. Rishi P, Mathur G, Rishi E. Fractured Ozurdex-implant in the vitreous cavity. Indian J Ophthalmol 2012;60(4):337-8
54. Kane FE, Burdan J, Cutino A, Green KE. Iluvien-: A new sustained delivery technology for posterior eye disease. Expert Opin Drug Deliv 2008;5(9):1039-46
55. Sakurai E, Ozeki H, Kunou N, Ogura Y. Effect of particle size of polymeric nanospheres on intravitreal kinetics. Ophthalmic Res 2000;33(1):31-6
56. Abrishami M, Ganavati SZ, Soroush D, et al. Preparation, characterization, and in vivo evaluation of nanoliposomesencapsulated bevacizumab (avastin) for intravitreal administration. Retina 2009;29(5):699-703
57. Lajavardi L, Bochot A, Camelo S, et al. Downregulation of endotoxin-induced uveitis by intravitreal injection of vasoactive intestinal peptide encapsulated in liposomes. Invest Ophthalmol Vis Sci 2007;48(7):3230-8
58. Prieto E, Puente B, Uixera A, et al. Gantrez AN nanoparticles for ocular delivery of memantine: In vitro release evaluation in albino rabbits. Ophthalmic Res 2012;48(3):109-17
59. Zhang L, Li Y, Zhang C, et al. Pharmacokinetics and tolerance study of intravitreal injection of dexamethasoneloaded nanoparticles in rabbits. Int J Nanomedicine 2009;4:175-83
60. Checa-Casalengua P, Jiang C, Bravo-Osuna I, et al. Retinal ganglion cells survival in a glaucoma model by GDNF/Vit E PLGA microspheres prepared according to a novel microencapsulation procedure. J Control Release 2011;156(1):92-100
61. Yandrapu SK, Upadhyay AK, Petrash JM, Kompella UB. Nanoparticles in porous microparticles prepared by supercritical infusion and pressure quench technology for sustained delivery of bevacizumab. Mol Pharm 2013;10(12):4676-86
62. Laurent UB, Fraser J. Turnover of hyaluronate in the aqueous humour and vitreous body of the rabbit. Exp Eye Res 1983;36(4):493-503
63. Oh EJ, Choi J-S, Kim H, et al. Anti-Flt1 peptide-Hyaluronate conjugate for the treatment of retinal neovascularization and diabetic retinopathy. Biomaterials 2011;32(11):3115-23
64. Sandrian MG, Wollstein G, Schuman JS, et al. Inflammatory response to intravitreal injection of gold nanorods. Br J Ophthalmol 2012;96(12):1522-9
65. Chaplot SP, Rupenthal ID. Dendrimers for gene delivery-A potential approach for ocular therapy? J Pharm Pharmacol 2013;66(4):542-56
66. Iezzi R, Guru BR, Glybina IV, et al. Dendrimer-based targeted intravitreal therapy for sustained attenuation of neuroinflammation in retinal degeneration. Biomaterials 2012;33(3):979-88
67. Marano R, Toth I, Wimmer N, et al. Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: A long-Term study into inhibition of laser-induced CNV, distribution, uptake and toxicity. Gene Ther 2005;12(21):1544-50
68. Parekh HS, Marano RJ, Rakoczy EP, et al. Synthesis of a library of polycationic lipid core dendrimers and their evaluation in the delivery of an oligonucleotide with hVEGF inhibition. Bioorgan Med Chem 2006;14(14):4775-80
69. Koo H, Moon H, Han H, et al. The movement of self-Assembled amphiphilic polymeric nanoparticles in the vitreous and retina after intravitreal injection. Biomaterials 2012;33(12):3485-93
70. Bourges JL, Gautier SE, Delie F, et al. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest Ophthalmol Vis Sci 2003;44(8):3562-9
71. Wong LL, Hirst SM, Pye QN, et al. Catalytic nanoceria are preferentially retained in the rat retina and are not cytotoxic after intravitreal injection. PLoS One 2013;8(3):e58431
72. Cai X, Seal S, McGinnis J. Sustained inhibition of neovascularization in vldlr (-/-) mice following intravitreal injection of cerium oxide nanoparticles and the role of the ASK1-P38/JNK-NF-kappaB pathway. Biomaterials 2014;35(1):249-58
73. Kim H, Csaky KG. Nanoparticle-integrin antagonist C16Y peptide treatment of choroidal neovascularization in rats. J Control Release 2010;142(2):286-93
74. Jin J, Zhou KK, Park K, et al. Anti-inflammatory and antiangiogenic effects of nanoparticle-mediated delivery of a natural angiogenic inhibitor. Invest Ophthalmol Vis Sci 2011;52(9):6230-7
75. Ryu M, Nakazawa T, Akagi T, et al. Suppression of phagocytic cells in retinal disorders using amphiphilic poly (gamma-glutamic acid) nanoparticles containing dexamethasone. J Control Release 2011;151(1):65-73
76. Zhang R, He R, Qian JA, et al. Treatment of experimental autoimmune uveoretinitis with intravitreal injection of tacrolimus (fk506) encapsulated in liposomes. Invest Ophthalmol Vis Sci 2010;51(7):3575-82
77. Liu H, Liu Y, Ma Z, et al. A Lipid nanoparticle system improves siRNA efficacy in RPE cells and a laserinduced murine CNV model. Invest Ophthalmol Vis Sci 2011;52(7):4789-94
78. Camelo S, Lajavardi L, Bochot A, et al. Drainage of fluorescent liposomes from the vitreous to cervical lymph nodes via conjunctival lymphatics. Ophthalmic Res 2008;40(3-4):145-50
79. Wang J, Liu Y, Li Y, et al. EphA2 targeted doxorubicin stealth liposomes as a therapy system for choroidal neovascularization in rats. Invest Ophthalmol Vis Sci 2012;53(11):7348-57
80. Honda M, Asai T, Umemoto T, et al. Suppression of choroidal neovascularization by intravitreal injection of liposomal SU5416. Arch Ophthalmol 2011;129(3):317-21
81. Ma L, Liu YL, Ma ZZ, et al. Targeted treatment of choroidal neovascularization using integrin-mediated sterically stabilized liposomes loaded with combretastatin A4. J Ocul Pharmacol Ther 2009;25(3):195-200
82. Li T, Zhang M, Han Y, et al. Targeting therapy of choroidal neovascularization by use of polypeptide-And PEDF-loaded immunoliposomes under ultrasound exposure. J Huazhong Univ Science Technol Med Sci 2010;30(6):798-803
83. Heilbronn R, Weger S. Viral vectors for gene transfer: Current status of gene therapeutics. In: Schäfer-Korting M, editor. Handbook of experimental pharmacology: Drug delivery. 197. Springer; Heidelberg: 2010. p. 143-70
84. Vandenberghe L, Auricchio A. Novel adeno-Associated viral vectors for retinal gene therapy. Gene Ther 2011;19(2):162-8
85. Lai C-M, Estcourt MJ, Wikstrom M, et al. rAAV. sFlt-1 gene therapy achieves lasting reversal of retinal neovascularization in the absence of a strong immune response to the viral vector. Invest Ophthalmol Vis Sci 2009;50(9):4279-87
86. Dalkara D, Byrne LC, Klimczak RR, et al. In vivo-directed evolution of a new adeno-Associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci Transl Med 2013;5(189):189ra76
87. Vandenberghe LH, Bell P, Maguire AM, et al. Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. Sci Transl Med 2011;3(88):88ra54
88. Mutalik S, Nayak U, Kalra R, et al. Sonophoresis-mediated permeation and retention of peptide dendrimers across human epidermis. Skin Res Technol 2012;18(1):101-7
89. Mitragotri S. Healing sound: The use of ultrasound in drug delivery and other therapeutic applications. Nat Rev Drug Discov 2005;4(3):255-60
90. Lentacker I, De Smedt SC, Sanders NN. Drug loaded microbubble design for ultrasound triggered delivery. Soft Matter 2009;5(11):2161-70
91. Peeters L, Lentacker I, Vandenbroucke RE, et al. Can ultrasound solve the transport barrier of the neural retina? Pharm Res 2008;25(11):2657-65
92. Huang SL. Liposomes in ultrasonic drug and gene delivery. Adv Drug Deliv Rev 2008;60(10):1167-76
93. Li H, Zheng X, Wang H, et al. Ultrasound-Targeted microbubble destruction enhances AAV-mediated gene transfection in human RPE cells in vitro and rat retina in vivo. Gene Ther 2009;16(9):1146-53
94. Zhou X-Y, Liao Q, Pu Y-M, et al. Ultrasound-mediated microbubble delivery of pigment epithelium-derived factor gene into retina inhibits choroidal neovascularization. Chin Med J (Engl Ed) 2009;122(22):2711-17
95. Paul S, Nahire R, Mallik S, Sarkar K. Encapsulated microbubbles and echogenic liposomes for contrast ultrasound imaging and targeted drug delivery. Comput Mech 2014;53(3):413-35
96. Suzuki R, Oda Y, Utoguchi N, Maruyama K. Progress in the development of ultrasound-mediated gene delivery systems utilizing nano-And microbubbles. J Control Release 2011;149(1):36-41
97. Sonoda S, Tachibana K, Yamashita T, et al. Selective gene transfer to the retina using intravitreal ultrasound irradiation. J Ophthalmol 2012;2012:Article ID 412752
98. Shen W, Li S, Chung SH, Gillies MC. Retinal vascular changes after glial disruption in rats. J Neurosci Res 2010;88(7):1485-99
99. Mannermaa E, Reinisalo M, Ranta V-P, et al. Filter-cultured ARPE-19 cells as outer blood-retinal barrier model. Eur J Pharm Sci 2010;40(4):289-96
100. Guduric-Fuchs J, Ringland LJ, Gu P, et al. Immunohistochemical study of pig retinal development. Mol Vis 2009;15:1915-28
101. Kobuch K, Herrmann WA, Framme C, et al. Maintenance of adult porcine retina and retinal pigment epithelium in perfusion culture: Characterisation of an organotypic in vitro model. Exp Eye Res 2008;86(4):661-8
102. Pow DV. Amino acids and their transporters in the retina. Neurochem Int 2001;38(6):463-84
103. Fletcher E, Jobling A, Vessey K, et al. Animal models of retinal disease. Progr Mol Biol Transl Sci 2011;100:211-86